Background
Prevention of HIV and unplanned pregnancies is a leading public health priority for women’s health. Multipurpose prevention technologies (MPTs) capable of delivering long-acting (LA) contraception and HIV prevention are needed. We recently demonstrated in-situ forming implants (ISFIs) in macaques can deliver cabotegravir (CAB) above protective benchmarks (>4 PA-IC90) for more than 5 months. Here, we assessed in macaques an MPT CAB ISFI co-formulated with medroxyprogesterone acetate (MPA) and a contrast agent for in vivo visualization. We define long-term safety, PK, and efficacy on inhibiting ovulation and reversal of contraception by implant removal.
Methods
Two 1-mL injections of ISFIs containing CAB (530 mg/mL), MPA (35 mg/mL) and 10% Barium-sulfate (BaSO4) were administered subcutaneously to 6 cycling pigtailed macaques. Plasma CAB, MPA, and progesterone were measured weekly for up to 6 months. ISFIs were surgically removed from 3 macaques at 3 months to assess contraceptive reversion. Implant site reactions were monitored using a modified Draize scale (0-4) and migration of ISFIs was assessed by X-ray imaging.
Results
Only one animal showed injection site reaction at one implantation site (grade 3) that self-resolved within a week. Overall, CAB ISFIs co-formulated with BaSO4 elicited slightly lower CAB release in macaques, confirming in vitro and in vivo mouse data. Median (range) plasma CAB and MPA concentrations during the first 3 months were 668 (416-899) and 1.04 (0.43-2.58) ng/mL, respectively (Fig 1a). Progesterone was fully suppressed in all animals (Fig 1b). Removal of ISFIs in 3 animals at month 3 resulted in undetectable CAB and MPA concentrations within 1-2 weeks and return to ovulation within 3-5 weeks. In the 3 macaques that maintained ISFIs, plasma CAB and MPA concentrations at month 6 were 562 (421-1,046) and 0.33 (0.29-0.38) ng/mL, respectively, with no return to ovulation. None of the animals had evidence of implant migration by X-ray imaging.
Conclusions
We report safety and long-term contraceptive efficacy of the first LA injectable MPT implant releasing CAB and MPA in macaques. Our findings showing a lack of implant migration are reassuring and suggest a limited value of adding BaSO4, particularly given the reduction in CAB release. Long-term suppression of ovulation after implantation and rapid reversal following removal suggest ISFIs may provide a discrete and flexible MPT option for adolescent girls and women.
Table or Figure
![]()